Catalog No.S1188

Anastrozole is a third-generation nonsteroidal selective aromatase inhibitor.

Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Anastrozole Chemical Structure

Anastrozole Chemical Structure
Molecular Weight: 293.37

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Aromatase Inhibitors
    Compare Aromatase Products
  • Research Area

Product Description

Biological Activity

Description Anastrozole is a third-generation nonsteroidal selective aromatase inhibitor.
Targets Aromatase
IC50 15 nM [1]
In vitro Anastrozole has high intrinsic potency in vitro and inhibits human placental aromatase with an IC50 of 15 nM. Anastrozole it is 200 times as potent as AG, twice as potent as 4-OHA and one third as potent as fadrozole. [1]. Anastrozole inhibits aromatase by binding competitively to the hem group of the CYP unit of the enzyme thereby reducing estrogen biosynthesis in the periphery and the breast. Anastrozole has little or no effect on other steroid hormones. [2]
In vivo Anastrozole (0.1 mg/kg) given orally to mature rats on Day 2 or 3 of the estrous cycle, blocked ovulation in mature females; in pubertal rats, the same dose given for 3 days completely blocks androstenedione-stimulated uterine development. These effects may be attributes to inhibition of the normal preovulatory rise in ovarian follicular estrogen synthesis in mature females and to inhibition of metabolism of the exogenous androstenedione by the immature ovary in prepubertal females. Twice-daily administration of >9.1 mg/kg of Anastrozole given orally to male pigtailed monkeys inhibits peripheral aromatase, thereby reducing circulating estradiol concentrations by 50% to 60%. [2]

Protocol(Only for Reference)



[1] Dukes M, et al. J Steroid Biochem Mol Biol, 1996, 58(4), 439-445.

[2] Plourde PV, et al. Breast Cancer Res Treat, 1994, 30(1), 103-111.

Clinical Trial Information( data from

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02057133 Recruiting Breast Neoplasms Eli Lilly and Company 2014-03 Phase 1
NCT02097459 Active, not recruiting Breast Cancer Peking Union Medical College Hospital 2014-03 Phase 3
NCT02089854 Not yet recruiting Female Breast Cancer Peking Union Medical College Hospital 2014-04 Phase 4
NCT01763541 Not yet recruiting Hypertension Massachusetts General Hospital 2014-06 Phase 0
NCT02093351 Not yet recruiting Solid Tumours AstraZeneca 2014-07 Phase 1

Chemical Information

Download Anastrozole SDF
Molecular Weight (MW) 293.37


CAS No. 120511-73-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms ZD-1033
Solubility (25°C) * In vitro DMSO 59 mg/mL (201 mM)
Water <1 mg/mL (<1 mM)
Ethanol 59 mg/mL (201 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Aromatase Products

  • PD123319

    PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

  • AZD3514

    AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.

  • Exemestane

    Exemestane is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.

    Features:17-hydroexemestane is the principal metabolite of Exemestane.

  • Letrozole

    Letrozole is a third generation inhibitor of aromatase with IC50 of 0.07-20 nM.

  • Aminoglutethimide

    Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.

    Features:A first-generation aromatase inhibitor used for estrogen-dependent breast cancer.

  • Formestane

    Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM.

  • Enzalutamide (MDV3100)

    Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM.

  • Tamoxifen Citrate

    Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

Recently Viewed Items

Tags: buy Anastrozole | Anastrozole ic50 | Anastrozole price | Anastrozole cost | Anastrozole solubility dmso | Anastrozole purchase | Anastrozole manufacturer | Anastrozole research buy | Anastrozole order | Anastrozole mouse | Anastrozole chemical structure | Anastrozole mw | Anastrozole molecular weight | Anastrozole datasheet | Anastrozole supplier | Anastrozole in vitro | Anastrozole cell line | Anastrozole concentration | Anastrozole nmr
Contact Us